Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGBOSE-50
- Development stage
- Unknown
- Lead developer
- CMG Biotech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CGBOSE-50 is an oral anti-diabetic formulation of acarbose (50 mg) developed and manufactured by CMG Biotech (CMG Pharmaceuticals). Acarbose is an alpha-glucosidase inhibitor that works locally in the small intestine. It competitively and reversibly inhibits membrane-bound intestinal alpha-glucosidase enzymes (such as maltase-glucoamylase and sucrase-isomaltase) as well as pancreatic alpha-amylase. By delaying the enzymatic hydrolysis of complex carbohydrates into absorbable monosaccharides, it slows down glucose absorption and reduces postprandial blood glucose spikes in patients with type 2 diabetes mellitus.
- Brand names
- CGBOSE-50CGBOSE50CGBOSE 50Cgbose
02
Targets
Sucrase-IsomaltaseAMY (Pancreatic alpha-amylase)
Beyond the preview
Go deeper on CGBOSE-50.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGBOSE-50.